Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [21] A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
    Shoji, Hirokazu
    Iwasa, Satoru
    Kuchiba, Aya
    Ogawa, Gakuto
    Kawasaki, Mamiko
    Nakamura, Kenichi
    Mori, Mikio
    Honma, Yoshitaka
    Takashima, Atsuo
    Kato, Ken
    Boku, Narikazu
    Okita, Natsuko
    Yamada, Yasuhide
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study)
    Nakamura, Masato
    Yamada, Takeshi
    Ishiyama, Shun
    Enomoto, Masanobu
    Yokomizo, Hajime
    Kosugi, Chihiro
    Sonoda, Hiromichi
    Ishimaru, Kei
    Ishibashi, Keiichiro
    Kuramochi, Hidekazu
    Nozawa, Keijiro
    Ohta, Ryo
    Takahashi, Makoto
    Yoshida, Hiroshi
    Hashiguchi, Yojiro
    Hirata, Keiji
    Katsumata, Kenji
    Ishida, Hideyuki
    Koda, Keiji
    Sakamoto, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
    Ducreux, M.
    O'Connor, J.
    Dochy, E.
    Fiala-Buskies, S.
    Cervantes, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 119 - 119
  • [24] Usefulness of Monthly Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer
    Tomoda, Mitsuhiro
    Kawahara, Hidejiro
    Watanabe, Kazuhiro
    Enomoto, Horoya
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2014, 34 (1A) : 191 - 194
  • [25] Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy
    Souglakos, J.
    Kalykaki, A.
    Vamvakas, L.
    Androulakis, N.
    Kalbakis, K.
    Agelaki, S.
    Vardakis, N.
    Tzardi, M.
    Kotsakis, A. P.
    Gioulbasanis, J.
    Tsetis, D.
    Sfakiotaki, G.
    Chatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 305 - 310
  • [26] Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    Saltz, Leonard B.
    Rosen, Lee S.
    Marshall, John L.
    Belt, Robert J.
    Hurwitz, Herbert I.
    Eckhardt, S. Gail
    Bergsland, Emily K.
    Haller, Daniel G.
    Lockhart, A. Craig
    Lima, Caio M. Rocha
    Huang, Xin
    DePrimo, Samuel E.
    Chow-Maneval, Edna
    Chao, Richard C.
    Lenz, Heinz J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4793 - 4799
  • [27] Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
    Graham, Christopher N.
    Maglinte, Gregory A.
    Schwartzberg, Lee S.
    Price, Timothy J.
    Knox, Hediyyih N.
    Hechmati, Guy
    Hjelmgren, Jonas
    Barber, Beth
    Fakih, Marwan G.
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1376 - 1391
  • [28] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Yong Sang Hong
    Jeeyun Lee
    Kyu-pyo Kim
    Jae-Lyun Lee
    Young Suk Park
    Joon Oh Park
    Se Hoon Park
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Tae-You Kim
    Tae Won Kim
    Investigational New Drugs, 2013, 31 : 183 - 191
  • [29] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [30] Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)
    Bozzarelli, Silvia
    Rimassa, Lorenza
    Giordano, Laura
    Sala, Simona
    Tronconi, Maria Chiara
    Pressiani, Tiziana
    Smiroldo, Valeria
    Prete, Maria G.
    Spaggiari, Paola
    Personeni, Nicola
    Santoro, Armando
    FUTURE ONCOLOGY, 2019, 15 (35) : 4009 - 4017
12345